Cogent Biosciences
COGT
134 hedge funds and large institutions have $1.1B invested in Cogent Biosciences in 2022 Q3 according to their latest regulatory filings, with 35 funds opening new positions, 46 increasing their positions, 36 reducing their positions, and 13 closing their positions.
360% more call options, than puts
Call options by funds: $1.42M | Put options by funds: $308K
169% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 13
74% more capital invested
Capital invested by funds: $633M → $1.1B (+$470M)
28% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 36
20% more funds holding
Funds holding: 112 → 134 (+22)
2.8% more ownership
Funds ownership: 110.32% → 113.12% (+2.8%)
22% less funds holding in top 10
Funds holding in top 10: 9 → 7 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$55M |
| 2 |
State Street
Boston,
Massachusetts
|
+$37.2M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$18.6M |
| 4 |
BlackRock
New York
|
+$17.8M |
| 5 |
SCM
Suvretta Capital Management
New York
|
+$17.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$39.9M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$30.6M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$14.7M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$10.3M |
| 5 |
ABG
Ally Bridge Group
New York
|
-$8.96M |
COGT Hedge Fund Activity: Q3 2022 in Review
134 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Cogent Biosciences (COGT) for Q3 2022, worth a combined $1.1B — up 74% from $633M a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new COGT positions and 13 closed out — a net gain of 22 holders — while 46 added to existing stakes and 36 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $55M. The largest seller was Deerfield Management, cutting an estimated $39.9M.
- 134 institutional investors held Cogent Biosciences (COGT) as of Q3 2022, up from 112 in Q2 2022.
- Funds reported $1.1B of Cogent Biosciences stock for Q3 2022, up 74% quarter-over-quarter.
- 35 funds opened new Cogent Biosciences positions in Q3 2022 and 13 closed out, a net change of +22 holders.
- The largest Cogent Biosciences buyer in Q3 2022 was RA Capital Management, an estimated $55M added.
- The largest Cogent Biosciences seller in Q3 2022 was Deerfield Management, an estimated $39.9M sold.
Based on aggregated 13F filings for Q3 2022.